| Dr Reddys Laboratories and Bayer announced that both companies have entered into a partnership to market and distribute a second brand of Vericiguat in India.
Under the terms of this agreement, Bayer has granted non-exclusive rights to Dr. Reddy's under the brand name Gantra®.
Vericiguat, a soluble guanylate cyclase (sGC) stimulator, in India, is indicated, along with guideline-based medical therapy, in adults with symptomatic chronic heart failure with reduced ejection fraction (less than 45%), following a recent event of worsening heart failure which required hospitalization or outpatient intravenous (IV) diuretics.
Vericiguat works on a pathway not currently targeted by existing
heart failure treatments and can reduce the combined risk of cardiovascular death and heart failure hospitalization in such patient . India has between 8-10 million people with heart failure, making it one
of the largest populations with this condition. |